Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 31, 2023

SELL
$80.93 - $108.63 $17,157 - $23,029
-212 Reduced 8.77%
2,206 $228,000
Q3 2022

Oct 26, 2022

SELL
$82.16 - $96.94 $24,319 - $28,694
-296 Reduced 10.91%
2,418 $205,000
Q2 2022

Aug 15, 2022

BUY
$71.48 - $86.85 $193,996 - $235,710
2,714 New
2,714 $225,000
Q3 2020

Nov 02, 2020

SELL
$71.87 - $131.03 $2,012 - $3,668
-28 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$79.55 - $124.22 $19,728 - $30,806
-248 Reduced 89.86%
28 $3,000
Q1 2020

May 18, 2020

BUY
$71.37 - $96.85 $19,698 - $26,730
276 New
276 $23,000
Q4 2019

Sep 02, 2020

SELL
$64.27 - $86.37 $2,377 - $3,195
-37 Closed
0 $0
Q3 2019

Nov 15, 2019

BUY
$67.4 - $85.11 $2,493 - $3,149
37 New
37 $2,000
Q1 2018

May 16, 2018

SELL
$77.67 - $92.63 $3,262 - $3,890
-42 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$80.76 - $95.13 $3,634 - $4,280
-45 Reduced 51.72%
42 $4,000
Q3 2017

Nov 15, 2017

BUY
$80.6 - $94.95 $7,012 - $8,260
87
87 $8,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Balentine LLC Portfolio

Follow Balentine LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balentine LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balentine LLC with notifications on news.